Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 15% Improvement Relative Risk ICU admission 2% Hospitalization 3% c19early.org/mf Wander et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 64,892 patients in the USA Lower mortality with metformin (p<0.000001) Wander et al., Diabetes Care, doi:10.2337/dc21-1351 Favors metformin Favors control
Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19
Wander et al., Diabetes Care, doi:10.2337/dc21-1351
Wander et al., Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19, Diabetes Care, doi:10.2337/dc21-1351
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 64,892 veterans with diabetes in the USA, showing lower mortality with existing metformin use.
risk of death, 15.0% lower, RR 0.85, p < 0.001, treatment 29,685, control 35,207, odds ratio converted to relative risk, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
risk of ICU admission, 1.9% lower, RR 0.98, p = 0.62, treatment 29,685, control 35,207, odds ratio converted to relative risk, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
risk of hospitalization, 3.2% lower, RR 0.97, p = 0.09, treatment 29,685, control 35,207, odds ratio converted to relative risk, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wander et al., 6 Oct 2021, retrospective, database analysis, USA, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Diabetes Care 1 Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19 Pandora L. Wander,1,2 Elliott Lowy,1,3 Lauren A. Beste,1,2 Luis Tulloch-Palomino,1,2 Anna Korpak,1 Alexander C. Peterson,1 Steven E. Kahn,1,2 and Edward J. Boyko1,2 https://doi.org/10.2337/dc21-1351 EPIDEMIOLOGY/HEALTH SERVICES RESEARCH OBJECTIVE To identify preinfection risk factors for adverse outcomes among veterans with diabetes and coronavirus disease 2019 (COVID-19) infection. RESEARCH DESIGN AND METHODS We identified all Veterans Health Administration patients with diabetes and one or more positive nasal swab(s) for severe acute respiratory syndrome coronavirus 2 (1 March 2020–10 March 2021) (n = 64,892). We examined associations of HbA1c and glucose-lowering medication use with hospitalization, intensive care unit (ICU) admission, and mortality at 30 days using logistic regression models and during 4.4 months of follow-up (range <1–13.1) using proportional hazards models. RESULTS Compared with HbA1c <7.0%, HbA1c ‡9.0% was associated with higher odds of hospitalization, ICU admission, and death at 30 days (odds ratio [OR] 1.27 [95% CI 1.19–1.35], 1.28 [95% CI 1.15–1.42], 1.30 [95% CI 1.17–1.44], respectively) as well as higher risk of death over 4.4 months (hazard ratio [HR] 1.22 [95% CI 1.12–1.32]). Insulin use was associated with higher odds of hospitalization, ICU admission, and death (OR 1.12 [95% CI 1.07–1.18], 1.12 [95% CI 1.04–1.22], and 1.18 [95% CI 1.09–1.27], respectively) and higher risk of death (HR 1.12 [95% CI 1.07–1.18]). Sodium–glucose cotransporter 2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonist (GLP1-RA), or angiotensin receptor blocker use were associated with lower odds of hospitalization (OR 0.92 [95% CI 0.85–0.99], 0.88 [95% CI 0.81–0.96], and 0.94 [95% CI 0.89–0.99], respectively). Metformin and SGLT2i use were associated with lower odds (OR 0.84 [95% CI 0.78–0.91], 0.82 [95% CI 0.72–0.94], respectively) and risk of death (HR 0.84 [95% CI 0.79–0.89], 0.82 [95% CI 0.74–0.92], respectively). 1 Veterans Affairs Puget Sound Health Care System, Seattle, WA 2 Department of Medicine, University of Washington, Seattle, WA 3 Department of Health Systems and Population Health, University of Washington, Seattle, WA Corresponding author: Pandora L. Wander, lwander@u.washington.edu CONCLUSIONS Received 28 June 2021 and accepted 10 September 2021 Among veterans with diabetes and COVID-19, higher HbA1c and insulin use were directly associated with adverse outcomes, while use of a GLP1-RA, metformin, and SGLT2i was inversely associated. This article contains supplementary material online at https://doi.org/10.2337/figshare.16629652 Diabetes is a risk factor for short-term adverse outcomes from coronavirus disease 2019 (COVID-19) (1). In a recent report, we identified risk factors for adverse short- © 2021 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www. diabetesjournals.org/content/license. Diabetes Care Publish Ahead of Print, published online October 6, 2021 2 Diabetes Care Diabetes and COVID-19 Outcomes in Veterans Table 1—Characteristics of VA veterans diagnosed with diabetes and COVID-19 Count (N = 64,892) % Female sex at birth 3,872 6 Age category,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit